Page 1

Active Biotech Q1 INTERIM REPORT Q2 2026 | ACTIVE BIOTECH AB We have taken important steps forward during the period and remain confident about the opportunities ahead EVENTS DURING THE SECOND QUARTER • Preclinical data with tasquinimod in myelodysplastic neoplasms published in HemaSphere ( April 14 ) Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye ( April 20 ) Active Biotech announced that European regulatory approval has been obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech , Oncode and HOVON ( May 13 ) EVENTS AFTER THE END OF THE PERIOD • First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis ( July 24 ) Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis ( August 18 ) FINANCIAL SUMMARY SEK M Net sales Apr - Jun 2026 2025 Jan - Jun 2026 2025 Full - year 2025 Operating profit / loss -10.2 -11.3 -18.8 -22.5 -37.6 Profit / loss after tax -10.1 -11.2 -18.4 -22.2 -37.3 Earnings per share ( SEK ) -0.38 -0.91 -0.70 -1.81 -2.77 Cash and cash equivalents ( at close of period ) 43.9 16.8 65.1 The report is also available at www.activebiotech.com The information was submitted , through the agency of the contact person below , for public disclosure on 2026-08-20 at 08:30 CEST . Active Biotech AB ( Corp. reg . no . 556223-9227 ) / Scheelevägen 22 , SE - 223 63 Lund / +46 46 192000 / www.activebiotech.com Helén Tuvesson , CEO : +46 46 19 21 56 , helen.tuvesson@activebiotech.com/ Hans Kolam , CFO : +46 46 192044 , hans.kolam@activebiotech.com